Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 10, Issue 4, Pages 982-985Publisher
LANDES BIOSCIENCE
DOI: 10.4161/hv.27637
Keywords
cancer immunotherapy; chimeric antigen receptor; HSC; T cell; gene therapy; suicide gene; HSV-TK
Categories
Funding
- UCLA Clinical and Translational Science Institute [UL1TR000124]
- Today's and Tomorrow's Children Fund (TTCF) [5T32 CA 9297-29]
- Hyundai Hope on Wheels
- St. Baldrick's Foundation
- European Hematology Association [TRTH30] Funding Source: researchfish
Ask authors/readers for more resources
The rapid expansion of available cancer immunotherapies has resulted in favorable early outcomes. Specifically the use of gene therapy to introduce chimeric antigen receptors (CARs) and T cell receptors (TCRs) in T cells creates new immunotherapy options for patients. While showing early success with these approaches, limitations remain that can be overcome by the use of modification of hematopoietic stem cells (HSCs) to express CARs and TCRs. With modern gene therapy technologies, increased safety and control of the modification of the HSCs can be achieved through the use of a suicide gene.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available